ESR1 and breast carcinoma: Taken together, our results show that NR2F2, GATA3, and FOXA1 can not only be used as markers for metastasis alone but are synergistic in inhibiting breast cancer metastasis, thereby contributing to the relatively low level of metastasis in ERα positive breast cancer compared with negative breast cancers.